Blood pressure-lowering drugs: Essential therapy for some patients with normal blood pressure

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 5, 2004, Pages 771-775

  Fuchs, Flávio Danni ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Blood pressure lowering drugs; Cardiovascular disease; Diabetes; Heart failure; Stroke

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; HYDRALAZINE; INDAPAMIDE; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; HYPERTENSION; RISK;

EID: 4544374978     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.5.771     Document Type: Article

References (30)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. J. Am. Med. Assoc. 202, 1028-1034 (1967).
3. Fuchs FD, Klag MJ, Whelton PK. The classics: a tribute to the 50th anniversary of the randomized clinical trial. J. Clin. Epidem. 53, 335-342 (2000).
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. J. Am. Med. Assoc. 213, 1143-1152 (1970).
5. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335, 827-838 (1990).
6. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. Br. Med. J. 304, 405-412 (1992).
7. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom. T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281-1285 (1991).
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J. Am. Med. Assoc. 265, 3255-3264 (1991).
9. Staessen JA, Fagard R, Thijs L et al. Randomized, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757-764 (1997).
10. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358, 1305-1315 (2001).
11. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J. Hypertens. 21, 1055-1076 (2003).
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). J. Am. Med. Assoc. 288, 2981-2997 (2002).
13. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
15. Svensson P, Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38, E28-E32 (2001).
16. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358, 1033-1041 (2001).
17. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362, 782-788 (2003).
18. The SOLVD investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685-691 (1992).
19. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 669-677 (1991).
20. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327, 669-677 (1992).
21. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100, 2312-2318 (1999).
22. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
23. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 90, 1765-1773 (1994).
24. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355 (1996).
25. Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
26. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. MEtoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
27. Poole-Wilson PA, Swedberg K, Cleland JG et al., and the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) randomized controlled trial. Lancet 362, 7-13 (2003).
28. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709-717 (1999).
29. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 335, 1107-1114 (1996).
30. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J. Am. Med. Assoc. 289, 2534-2544 (2003).